BioSpace News Archive

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team

BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in two upcoming virtual investor conferences.

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D’s Audit and Risk Committee and will serve as the Company’s “audit committee financial expert”

Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Miroculus, Inc., a developer of revolutionary tools for personal lab automation today announced new research optimizing an automated PCR-free Whole Genome Sequencing (WGS) library prep workflow for very low input human samples.

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Byung Ha Lee, Ph.D., as Chief Scientific Officer (CSO) effective March 1 st , 2021. Dr. Lee brings extensive scientific experience to the leadership team, with over 15 years of diverse drug development experience. In this new role, Dr. Lee will lead the effort to further demonstrate the scientific strength

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for full-year ended December 31, 2020, and host a corporate update conference

Bioengineering is the application of engineering technology and methods to the field of biology. Polymer of amino acids, proteins play a significant role in facilitating smooth functioning of the human body.

The global erythropoietin drugs market is prognosticated to demonstrate steady growth in coming years, as reported by Transparency Market Research.